Use and effectiveness of eltrombopag in a tertiary hospital
Use and effectiveness of eltrombopag in a tertiary hospital
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
Background Eltrombopag is authorised by the EMA for adult chronic immune thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments and as second-line treatment for non-splenectomised patients for whom surgery is contraindicated. Eltrombopag was effective in 59% of patients in a randomised controlled trial (Bussel...
Alternative Titles
Full title
Use and effectiveness of eltrombopag in a tertiary hospital
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1784194719
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1784194719
Other Identifiers
ISSN
2047-9956
E-ISSN
2047-9964
DOI
10.1136/ejhpharm-2012-000074.408
